The Space: Life Sciences Podcast

For years, biopharma companies competed in what one analyst called a "sales-force arms race," believing more reps meant better results. That era is long gone, but today's commercial challenge is arguably even more difficult.  Physician access has become increasingly scarce, while commercial organizations have grown more specialized. Sales, medical, market access, and other functions each play a cr...

As biotech navigates a mixed funding and dealmaking environment in 2026, one principle continues to guide the commercial playbook: capital efficiency. So says Jacob Lai, Vice President and Head of Commercial at Star Therapeutics, who sat down with Marc Iskowitz in the latest episode of The Space Life Sciences Podcast to discuss how that environment is shaping go-to-market strategy. Jacob explains...

"If the evidence is compelling, why isn't practice evolving?" That was Audrey Carnevale's “welcome to pharma” moment — the realization that strong data doesn't automatically translate into changes in clinical adoption. Now Associate Director of Medical Communications at Averitas Pharma (and an MSL before that), Audrey joins Marc Iskowitz in the second episode of The Space pod...

Operating model. Launch readiness. Data. Execution. Get these wrong, and even the most promising therapy can stall. Get them right, and you get product to patient — and that’s what drives Lori Nemyier every day.  In this inaugural episode of the  Space Life Sciences Podcast , Marc Iskowitz sits down with Lori to unpack a critical question for emerging biotechs: Why do so many companies struggle to...